Name：Lu Xi

Department：Pharmacology

Tel: (8610)67058991

Email: xilu@imb.pumc.edu.cn

Education & Research

2016/9-Now, Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2013/6-2016/8, Assistant Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2007/9-2013/6 Ph.D. in microbial and biochemical pharmacy, Peking Union Medical College

2003/9-2007/6 Bachelor in pharmacy, Xiangya Medical School of Central South University.

2010/10-2012/10, 2019/1-2019/12 Research scholar, Harvard Medical School.

Research Field：

Discovery, pharmacodynamics and mechanism of action of antibacterial agents; design and research of antibacterial vaccine.

Research Interests：

Dr. Lu’s research encompasses discovery, pharmacodynamic and mechanisms of action study of the new antibacterial compounds. Besides, she devotes to the design and evaluation of vaccines against major human bacterial pathogens such as Escherichia coli and Klebsiella pneumoniae.

Selected Publications

1. Li ZW*, Lu X*, Wang YX, Hu XX, Fu HG, Gao LM, You XF, Tang S, Song DQ. Synthesis and antibacterial evaluation against resistant Gram-negative bacteria of monobactams bearing various substituents on oxime residue. Bioorg Chem. 2020 Jan; 94:103487.

2. Yang YS*, Lu X*, Zeng QX, Pang J, Fan TY, You XF, Tang S, Wang YX, Song DQ. Synthesis and biological evaluation of 7-substituted cycloberberine derivatives as potent antibacterial agents against MRSA. Eur J Med Chem. 2019 Apr 15; 168:283-292.

3. Yang YS, Tang S, Liu ZD, Wang YX, Pang J, You XF, Song DQ, Li YH*, Lu X*. Synthesis and antibacterial evaluation of sulbactam derivatives against Acinetobacter baumannii. Pharmazie. 2018; 73 (8): 433-437

4. Lu X*, Skurnik D*, Pozzi C, Roux D, Cywes-Bentley C, Ritchie JM, Munera D, Gening ML, Tsvetkov YE, Nifantiev NE, Waldor MK, Pier GB. A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli. mBio. 2014 Mar 25;5(2):e00974-14.

5. Lu X*, Yang X*, Li X, Lu Y, Ren Z, Zhao L, Hu X, Jiang J, You X. In vitro activity of sodium new houttuyfonate alone and in combination with oxacillin or netilmicin against methicillin-resistant Staphylococcus aureus. PLoS One. 2013 Jul 2;8(7):e68053.

6. Skurnik D, Roux D, Pons S, Guillard T, Lu X, Cywes-Bentley C, Pier GB. Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016 Apr;71(4):927-35.

7. An D, Oh SF, Olszak T, Neves JF, Avci FY, Erturk-Hasdemir D, Lu X, Zeissig S, Blumberg RS, Kasper DL. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell. 2014 Jan 16;156(1-2):123-33.

8. Skurnik D, Roux D, Cattoir V, Danilchanka O, Lu X, Yoder-Himes DR, Han K, Guillard T, Jiang D, Gaultier C, Guerin F, Aschard H, Leclercq R, Mekalanos JJ, Lory S, Pier GB. Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20747-52.

9. Cywes-Bentley C, Skurnik D, Zaidi T, Roux D, Deoliveira RB, Garrett WS, Lu X, O'Malley J, Kinzel K, Zaidi T, Rey A, Perrin C, Fichorova RN, Kayatani AK, Maira-Litràn T, Gening ML, Tsvetkov YE, Nifantiev NE, Bakaletz LO, Pelton SI, Golenbock DT, Pier GB. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):E2209-18.

10. Li CR, Zhai QQ, Wang XK, Hu XX, Li GQ, Zhang WX, Pang J, Lu X, Yuan H, Gordeev MF, Chen LT, Yang XY, You XF. In vivo antibacterial activity of MRX-I, a new oxazolidinone. Antimicrob Agents Chemother. 2014;58(4):2418-21.